Robijns Jolien, Aquilano Michele, Banerjee Suvam, Caini Saverio, Wolf Julie Ryan, van den Hurk Corina, Beveridge Mara, Lam Henry, Bonomo Pierluigi, Chow Edward, Behroozian Tara
Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Hasselt, Belgium.
Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Support Care Cancer. 2023 Mar 17;31(4):219. doi: 10.1007/s00520-023-07671-0.
This systematic review and meta-analysis aimed to evaluate the efficacy of barrier films and dressings in preventing acute radiation dermatitis (RD).
OVID Medline, Embase, and Cochrane databases were searched from 1946 to September 2020 to identify randomized controlled trials on the use of barrier films or dressings to prevent RD. For comparable outcomes between studies, pooled effect sizes and 95% confidence intervals (CI) were calculated using the random effects analysis in RevMan 5.4.
Fourteen and 11 studies were included in the qualitative and quantitative analyses, respectively. Five types of barrier films used for RD were identified: Hydrofilm, StrataXRT®, Mepitel® Film, 3 M™ Cavilon™ No-Sting Barrier Film, and silver leaf nylon dressing. Hydrofilm and Mepitel Film significantly reduced the development of RD grade ≥ 2 in breast and head and neck cancer patients (RR 0.32, 95%CI 0.19, 0.56, p < 0.0001; RR 0.21, 95%CI 0.05, 0.89, p = 0.03, resp.). Moreover, Hydrofilm had a beneficial effect on patient-reported outcomes (PROs) (SMD -0.75, 95%CI -1.2, -0.29, p = 0.001). The meta-analyses on the other barrier films did not show any significant effect.
This review and meta-analysis demonstrated that Hydrofilm and Mepitel Film could effectively reduce RD severity and improve PROs. The evidence is generally weak for all the studies on barrier films and dressings due to a limited study number, high risk of bias, small sample sizes, and minimal comparable outcome measures. It's potential has been proven, but future research in this field is recommended to confirm the efficacy of these products and assess real-world feasibility.
本系统评价和荟萃分析旨在评估屏障膜和敷料在预防急性放射性皮炎(RD)方面的疗效。
检索1946年至2020年9月的OVID Medline、Embase和Cochrane数据库,以确定关于使用屏障膜或敷料预防RD的随机对照试验。对于研究间可比的结局,使用RevMan 5.4中的随机效应分析计算合并效应量和95%置信区间(CI)。
定性分析和定量分析分别纳入了14项和11项研究。确定了用于RD的5种类型的屏障膜:水凝胶膜、StrataXRT®、美皮康薄膜、3M™ Cavilon™ 无刺痛屏障膜和银叶尼龙敷料。水凝胶膜和美皮康薄膜显著降低了乳腺癌、头颈癌患者中≥2级RD的发生率(RR 0.32,95%CI 0.19,0.56,p<0.0001;RR 0.21,95%CI 0.05,0.89,p=0.03)。此外,水凝胶膜对患者报告结局(PROs)有有益影响(SMD -0.75,95%CI -1.2,-0.29,p=0.001)。对其他屏障膜的荟萃分析未显示任何显著效果。
本评价和荟萃分析表明,水凝胶膜和美皮康薄膜可有效降低RD严重程度并改善PROs。由于研究数量有限、偏倚风险高、样本量小以及可比结局测量指标极少,所有关于屏障膜和敷料的研究证据总体较弱。其潜力已得到证实,但建议该领域未来的研究确认这些产品的疗效并评估实际可行性。